Lipocine (NASDAQ:LPCN) Sees Strong Trading Volume

Lipocine Inc (NASDAQ:LPCN) saw unusually-high trading volume on Wednesday . Approximately 1,354,959 shares were traded during trading, an increase of 10% from the previous session’s volume of 1,233,565 shares.The stock last traded at $0.48 and had previously closed at $0.47.

LPCN has been the topic of several recent analyst reports. LADENBURG THALM/SH SH downgraded shares of Lipocine from a “buy” rating to a “neutral” rating in a research note on Monday, November 11th. ValuEngine raised shares of Lipocine from a “sell” rating to a “hold” rating in a research note on Monday, November 11th. Finally, HC Wainwright reduced their price objective on shares of Lipocine from $5.00 to $2.00 and set a “hold” rating on the stock in a research note on Monday, November 11th.

The company has a quick ratio of 3.31, a current ratio of 3.31 and a debt-to-equity ratio of 0.61. The firm has a market cap of $12.19 million, a PE ratio of -0.86 and a beta of 0.18. The firm’s 50 day moving average is $0.46 and its 200-day moving average is $1.57.

A number of hedge funds have recently modified their holdings of LPCN. Millennium Management LLC acquired a new position in Lipocine during the third quarter worth approximately $67,000. BlackRock Inc. increased its position in Lipocine by 17.2% during the second quarter. BlackRock Inc. now owns 364,196 shares of the specialty pharmaceutical company’s stock worth $710,000 after purchasing an additional 53,535 shares during the last quarter. Renaissance Technologies LLC increased its position in Lipocine by 212.3% during the fourth quarter. Renaissance Technologies LLC now owns 1,901,256 shares of the specialty pharmaceutical company’s stock worth $732,000 after purchasing an additional 1,292,484 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Lipocine by 15.7% during the second quarter. Vanguard Group Inc. now owns 555,868 shares of the specialty pharmaceutical company’s stock worth $1,084,000 after purchasing an additional 75,245 shares during the last quarter. 12.18% of the stock is owned by hedge funds and other institutional investors.

About Lipocine (NASDAQ:LPCN)

Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.

See Also: Do You Need a Fiduciary?

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.